The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC)

John R. Yannelli, Jamie Sturgill, Terry Foody, Edward Hirschowitz

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

In the current study, we generated large numbers of dendritic cells (DCs) from patients with non-small cell lung cancer (NSCLC) for a vaccine trial. The DCs were generated from CD14+ cells obtained by immuno-magnetic bead column separation technique. The CD14+ cells were placed in culture in the presence of granulocyte macrophage colony stimulating factor (GMCSF) and Interleukin 4 (IL-4). At Day 7, apoptotic bodies derived from an allogeneic NSCLC line 1650-TC were added to the cultures at a DC:tumor cell ratio of 1:1. At Day 8, the DCs were harvested, washed and injected intradermally into patients. Using this protocol we have prepared DCs for 16 patients. An average of 9.3 × 10 7 DCs was injected for the priming dose and 8.2 × 10 7 DCs for the boost. Clinical evaluation of the patients and immune assessment are presented in a separate report. The current report provides evidence for the large scale production of functional DCs derived from patients with NSCLC which can be used as vaccines in clinical trials.

Original languageEnglish
Pages (from-to)337-350
Number of pages14
JournalLung Cancer
Volume47
Issue number3
DOIs
StatePublished - Mar 2005

Bibliographical note

Funding Information:
We would like to acknowledge the cell separation center at the University of Kentucky for their expertise in providing the leukapheresis products obtained from the 16 patients. In addition, we thank Dr. Joanne Wroblewski for help with the laboratory protocol. Finally, we would like to express deepest gratitude to the 16 patients who through informed consent agreed to participate in this clinical trial. These patients were keenly aware that while the current study may not have impacted them in a positive way, it was clearly providing important information to allow us to improve future therapies. We believe we have gained a greater understanding of the immune response to this deadly disease, thanks to these willing individuals. Funding for the work in this grant was provided by the Kentucky Lung Cancer Research Fund and the Cancer Treatement Research Foundation (CTRF).

Keywords

  • Apoptotic bodies
  • DC maturation
  • Dendritic cell
  • Immunization
  • Immunotherapy
  • Non-small cell lung cancer (NSCLC)
  • T cells
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC)'. Together they form a unique fingerprint.

Cite this